The complexity of regulation of IFN signaling in prostate cancer and the putative roles that ISGs exert in this malignancy, underscore the prospect of developing therapy combinations which alter ISG expression or exploit their lack of expression. The gene discussed is IFNA1; the disease is prostate cancer.